Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
4 hedge funds and large institutions have $1.6M invested in Proshares UltraPro NASDAQ Biotechnology in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
144% more capital invested
Capital invested by funds: $655K → $1.6M (+$944K)
2.12% more ownership
Funds ownership: 1.65% → 3.76% (+2.1%)
2% more call options, than puts
Call options by funds: $728K | Put options by funds: $712K
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$568K |
| 2 |
Jane Street
New York
|
+$350K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$3.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$131K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$49K |
| 3 |
Morgan Stanley
New York
|
-$70 |
UBIO Hedge Fund Activity: Q3 2017 in Review
4 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q3 2017, worth a combined $1.6M — up 144% from $655K a quarter earlier.
Fund positioning in UBIO was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $568K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $131K sold.
- 4 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $1.6M of Proshares UltraPro NASDAQ Biotechnology stock for Q3 2017, up 144% quarter-over-quarter.
- 2 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q3 2017 and 2 closed out, a net change of 0 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q3 2017 was Susquehanna International Group, an estimated $568K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q3 2017 was Tower Research Capital (TRC), an estimated $131K sold.
Based on aggregated 13F filings for Q3 2017.